Life Sciences workshops - Valuation from a start-up perspective

Date

07.02.2019 15:00 - 18:30

Location

Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil

Register

Follow this Link

Author

Lea Lindler

The purpose of this workshop is to decrypt the reasons behind using rNPV or VC methodologies to value a product or a Biotech company.

The risk adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage. Well-calibrated the rNPV method is a powerful tool to build, challenge and value the company’s strategy. It also shows how the value of the company develops along reaching milestones. Is it however enough for investors?
 
From an investor’s perspective it is crucial to understand how long it takes before an exit and what is the potential for ROI (Return on Investment). They need to figure out the conditions to harvest their investment as well as to anticipate the multiple later-round investors and incentive packages to key employees that may dilute their stake. Learn the how’s and when’s of using the rNPV method versus the venture capital method.


rss